Keywords : Apolipoprotein E
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 126-133
Introduction: Psoriasis is a chronic skin disease of unclear aetiology and pathogenesis
which is characterized by an inflammatory infiltration in dermis and epidermis,
proliferation of epidermal cells – keratinocytes which clinically manifests with the
formation of erythemato-squamose papules, and is often accompanied by the
engagement of joints and nails in the process of inflammation.
Materials and Methods: This is a case-control study conducted at Department of
Biochemistry, Central Research Lab and Central Clinical Lab of GMC Azamgarh. The
subjects will be selected as per the inclusion/ exclusion criteria. A detailed clinical
history including age, sex, and occupation will be collected from the patients after
obtaining written and informed consent. For ApoE: Genomic Dna is extracted from
blood using QIAamp DNA minikit. The genotypes of the APOE polymorphisms is
determine by using APOE strip assay kit based on polymerase chain reaction and
Result: A total of 380 patients who fulfilled the selection criteria during the study were
enrolled, they were divided into two groups case and control each group consist of 190
patients. Maximum number of (41.5%) patients are seen during <1 years of duration of
psoriasis followed by 1-2 years are 27.8%, 2-3 years are 22.1% and least are 4-5 years
are 1.5%. Most of the patients has plaque type of psoriasis are 88.4% followed by
Guttate 8.9% and few are Pustular and Exfoliative 1.5% and 1.0% respectively.
Severity of psoriasis is mild 17.8%, moderate 48.4% and severe 33.6%. Apolipoprotein
E alleles in cases are𝜀3 83.1% followed by 𝜀4 12.1% and 𝜀2 4.7%. On the other hand, in
control group 𝜀3 94.2% and 𝜀4 10%.
Conclusion: Apolipoprotein E may be used as a marker to predict those patients with
psoriasis who are at risk of dyslipidemia and probably CVD. Based on the results of our
study, we recommend regular monitoring of patients with psoriasis for the presence of
comorbidities which have a definite adverse effect on both psoriasis and the CVS.